Related Experiment Video
Updated: Mar 25, 2026

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
Artesunate as an Anti-Cancer Agent Targets Stat-3 and Favorably Suppresses Hepatocellular Carcinoma
M Ilamathi, S Santhosh, V Sivaramakrishnan1
1Department of Bioinformatics, CTOR Lab, School of Chemical and Biotechnology, SASTRA University, Thirumalaisamudram, Thanjavur-613401, Tamilnadu, India. sivaramakrishnan@scbt.sastra.edu.
Background:
Aberrant signal transducer and activator of transcription 3 (STAT-3) molecular signaling elicit hepatocellular carcinoma (HCC) in humans. Therefore, targeting STAT-3 is considered as an attractive option towards suppression of HCC in humans.
Objective:
Our objective is to identify a potential small molecule inhibitor that can specifically target STAT-3 and suppress HCC.
Methods:
In this study, we analyze a group of sesquiterpene lactone (STL) candidates that has been recently reported in preclinical trials against cancer by a unified computational and experimental approach.
Results:
Our virtual analysis of the STL candidates revealed Artesunate (ATS) as the best potential inhibitor of STAT-3 with comparable potency to specific inhibitor S3I-201. We also observed that ATS inhibited IL-6 driven STAT-3-DNA binding activity with comparable potency to S3I-201 in a cell free system. Furthermore ATS was observed to interfere with STAT-3 dimerization and suppression of both constitutive and IL-6 inducible STAT-3 in vitro. Nevertheless, we also observed that ATS modulated STAT-3 dependent targets (procaspase-3, Bcl-xl and survivin) favoring occurrence of apoptosis in vitro. Overall, the putative inhibition of STAT-3 by ATS suggested its capacity to interfere with STAT-3 dimerization by binding to the SH2 domain of STAT-3 monomer. It resulted in suppression of STAT-3 and also favored promotion of in vitro cells towards apoptosis. Consequently, ATS also exhibited selective cytotoxicity of cancer cells over normal cells in vitro.
Conclusion:
All the above observations substantiated by unified computational and in vitro experimental approaches suggested its potential role as a therapeutic anti-cancer agent against HCC.
Insights
Artesunate (ATS) shows potential as a hepatocellular carcinoma (HCC) therapeutic by inhibiting signal transducer and activator of transcription 3 (STAT-3) signaling. This small molecule effectively suppresses cancer cell growth and promotes apoptosis in vitro.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacology
Background:
- Aberrant signal transducer and activator of transcription 3 (STAT-3) signaling is implicated in hepatocellular carcinoma (HCC) development.
- Targeting STAT-3 presents a promising therapeutic strategy for HCC suppression.
Purpose of the Study:
- To identify a small molecule inhibitor that specifically targets STAT-3 for HCC suppression.
- To evaluate sesquiterpene lactone (STL) candidates as potential STAT-3 inhibitors.
Main Methods:
- Utilized a unified computational and experimental approach to analyze STL candidates.
- Assessed Artesunate's (ATS) inhibitory effects on STAT-3 activity, dimerization, and downstream targets in vitro.
- Investigated ATS's impact on STAT-3 DNA binding and its cytotoxicity against cancer cells.
Main Results:
- Artesunate (ATS) identified as a potent STAT-3 inhibitor, comparable to S3I-201.
- ATS inhibited IL-6 driven STAT-3-DNA binding and STAT-3 dimerization in vitro.
- ATS modulated STAT-3 dependent pro-apoptotic targets and exhibited selective cytotoxicity towards HCC cells.
Conclusions:
- The study suggests ATS has potential as a therapeutic agent against HCC.
- ATS demonstrates efficacy through STAT-3 inhibition, promoting apoptosis and selective cancer cell cytotoxicity.
- Combined computational and in vitro data support ATS's role in HCC therapy.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

